SCHEMBL13348341

SCHEMBL13348341

CCN(c1ccc(C)c2cc(C)[nH]c12)S(=O)(=O)c1cccs1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.38
MAPT P10636 6/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
TSHR P16473 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
OXTR P30559 1/20 0.35
HSD17B10 Q99714 1/20 0.34
POLB P06746 1/20 0.34
LMNA P02545 1/20 0.34
PKM P14618 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13222026 0.87 ALDH1A1 (0.36) ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1
SCHEMBL1654068 0.86 ALDH1A1 (0.39) ALDH1A1MAPTSMN1; SMN2L3MBTL1TSHR
SCHEMBL1653263 0.85 ALDH1A1 (0.39) ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1
SCHEMBL1654799 0.84 ALDH1A1 (0.36) ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1
SCHEMBL1653230 0.84 L3MBTL1 (0.38) ALDH1A1MAPTSMN1; SMN2L3MBTL1TSHR
SCHEMBL13674999 0.83 MAPT (0.38) ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1
SCHEMBL13348338 0.81 MAPT (0.34) ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1
SCHEMBL2968702 0.80 MAPT (0.35) ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1
SCHEMBL1653362 0.79 ALDH1A1 (0.35) ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1
SCHEMBL1654129 0.79 MAPT (0.33) ALDH1A1MAPTL3MBTL1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144702-A1 INDOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-10 US disclosed
US-7652133-B2 Indole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-26 US disclosed
US-20080096877-A1 Glucokinase activators; prophylaxis or treatment of diabetes, obesity; sulfonamide or sulfonate-functional thiazole or thiadiazole-substituted indoles; N,N-dimethyl-2-{4-[(2-{7-[methyl(2-thienylsulfonyl)amino]-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]piperazin-1-yl}acetamide for example TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144702-A1 INDOLE COMPOUND GCKR, GPR119, SLC5A1 ALDH1A1 376/4885MAPT 4224/4885SMN1; SMN2 4708/4885
US-20080096877-A1 Glucokinase activators; prophylaxis or treatment of diabetes, obesity; sulfonamide or sulfonate-functional thiazole or thiadiazole-substituted indoles; N,N-dimethyl-2-{4-[(2-{7-[methyl(2-thienylsulfonyl)amino]-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]piperazin-1-yl}acetamide for example GCKR, GCK, KHK ALDH1A1 296/4885MAPT 4496/4885SMN1; SMN2 4181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.